About this episode
In this episode we welcome Rob Roscow, Co-Founder & Chief Scientific Officer at Mydecine Innovations Group.
Mydecine has government, military, and academic research contracts across numerous countries and is heavily invested in development of a novel molecule pipeline that includes treatments intended for smoking cessation and treatment of PTSD.
I had a chance to meet Rob and the Mydecine team in-person at the 2021 Telluride Mushroom Festival, which was sponsored by Mydecine.
This episode dives into the Mydecine drug development pipeline and the entourage effect of mushrooms through a biopharmaceutical lens.
It's an arena of study which I am largely unfamiliar with, but which is becoming increasingly important in lobbying for the mainstream acceptance and regulatory scrutiny of psychedelic medicines as legitimate and effective therapeutic tools.
Hosted on Acast. See acast.com/privacy for more information.
Get every episode summarized
Each time Mycopreneur publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Mycopreneur
Lee Carroll: Ergothioneine in Support of Psychedelic Therapy
Mycopreneur
Adam Miezio: Psychedelics in the Epstein Files
Mycopreneur
Robert Gallery: Ibogaine For Athletes with Traumatic Brain Injuries
Mycopreneur
Melanie Tremblay: The Hidden Dangers of AI-Generated Mushroom Claims
Mycopreneur